Chronic impact of traumatic brain injury on outcome and quality of life: a narrative review

Table 1 Outcome at 6 months (percent data) from major pharmacological trials and consecutive series

	Publication year	Patient number	Death	Vegetative state	Severe disability	Moderate disability	Good recovery
Neuroprotective trials: placebo groups
Tirilazad [82]	1998	459	28	4	13	17	38
Metilprednisolone [48]	2005	4819	22	Included in the mortality rate	14	17	46
Progesteron [83]	2014	588	22	Not reported	27	19	31
Consecutive series
EBIC [84]	1999	796	31	2	16	20	31
NeuroLink [85]	2012	1273	33	3	14	17	33
UK RAIN study [86]	2013	2620	26	Not reported	33	22	19

Results at 6 months shown in this table are not corrected for severity. Better results in the neuroprotective trials may depend on the exclusion of the most severe cases, who are not amenable to randomization but are, on the contrary, included in consecutive series. The Metilprednisolone study included severe and moderate TBI

ISSN: 1364-8535